ClinicalTrials.gg
CompletedNCT04034134Updated Nov 29, 2022

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

A Phase 2 interventional study of Jaktinib Hydrochloride Tablets and Jaktinib Hydrochloride Tablets in Alopecia Areata, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Enrollment
17th of 22
111 · median 163
Started
2019
with 2 others
Phase 2
6 of 24
2 open now
Registered
5th of 24
by date
Lead sponsor
4 of 24
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 24 studies in Alopecia Areata with a site in China, this one is the 17th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 2, and was the 5th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years age or older ,male or female;
  • Alopecia areata diagnosed clinically;
  • Patients with alopecia accounting for 50% or more of the total scalp area and stable for at least 6 months or more;
  • Patients can complete treatment for at least six months;
  • Requirements for pregnant or lactating female and male and female of childbearing age;Female patients must be satisfied:Menopause (defined as no menstruation for at least one year);Or have been surgically sterilized;Or have fertility, but must satisfy:Pregnancy tests conducted within 7 days before randomization must be negative;And agree to use appropriate methods throughout the trial period, including at least one barrier method;And no breastfeeding;Male patients must agree to use appropriate contraceptive measures throughout the trial, including at least one barrier method;
  • Patients are voluntarily enrolled in the Study and can be treated and visited according to the requirements of the protocol after signing the Form;

Exclusion criteria

Exclusion Criteria:

  • Alopecia caused by syphilitic alopecia, thyroid disease, trichotilomania, head moss, connective tissue disease, infection, zinc deficiency and iron deficiency;
  • Patients with acute diffuse alopecia areata (ADTAFS)
  • Patients with active tuberculosis
  • The following diseases were combined within 6 months before randomization:thyroid diseases ,liver diseases, malnutrition, heart diseases, nervous system diseases, gastrointestinal disorders, tumors and psychiatric diseases
  • positive, active virus positive (HBsAg or HBeAg positive) and positive at screening;
  • Other patients with abnormal history or clinical manifestations that may affect participants participation in the study or may confuse the results of the study;
  • Within two weeks before randomization,Patients who received topical therapy, anthracene ointment, minoxidil, SADBE/DPCP contact immunotherapy, photochemotherapy or cryotherapy;
  • Before randomization,oral or injected any medicines to treat hair loss (including the glucocorticoids was detected in injection, systemic corticosteroids, antihistamines, stephania drugs, glycyrrhizin, glycine, methionine compound tablet, compound glycyrrhizin glucoside) and other liquorice extract, ring spore element, anti TNF antibody, IFN - gamma, IL - 2 antibodies, for alopecia areata therapy of traditional Chinese medicine and other JAK inhibitor) and less than seven half-life of patients;
  • Participants in a clinical trial of any drug or medical device within 4 weeks prior to randomization.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Jaktinib Hydrochloride Tablets 50mg bid

    Oral tablet for 24 weeks

    Drug: Jaktinib Hydrochloride Tablets

  • Experimental
    Jaktinib Hydrochloride Tablets 150mg qd

    Oral tablet for 24 weeks

    Drug: Jaktinib Hydrochloride Tablets

  • Experimental
    Jaktinib Hydrochloride Tablets 200mg qd

    Oral tablet for 24 weeks

    Drug: Jaktinib Hydrochloride Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Effective rate

    Effective rate = (cure + obvious effect + effective)/total cases \*100%;

    Time frame: From randomization of the first subject until the last subject complete 6 months treatment

Secondary outcomes

  1. SALT score change

    Score and take photos (4 areas on the head), taking photos in the same position and light condition each time;

    Time frame: From randomization of the first subject until the last subject complete 6 months treatment

  2. Quality of Life (AASIS)

    AASIS was used to score the quality of life of the subjects

    Time frame: From randomization of the first subject until the last subject complete 6 months treatment

Other outcomes

  1. Safety variables will be summarized using descriptive statistics based on adverse events collection

    Patients with adverse events/all patients \*100%

    Time frame: From randomization of the first subject until the last subject complete 6 months treatment

07

Study locations

2 sites
  • Chongqing Chinese Traditional Medicine Hospital
    Chongqing, Chongqing 400011, China
  • The second xaingya hospital of central south university
    Changsha, Hunan 410011, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Nov 2021, 24 months.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 26, 2019
StartActual
Nov 18, 2019
Primary completionActual
Nov 26, 2021
CompletionActual
Nov 26, 2021
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04034134
Responsible party
Sponsor
First posted
Jul 26, 2019
Start date
Nov 18, 2019
Primary completion
Nov 26, 2021
Completion
Nov 26, 2021
Last update
Nov 29, 2022

Study contacts

qianjin Lu, MD
principal investigator · Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion